Preliminary evaluation of in-Vivo and in-Vitro antifungal activity of Piper longum, Origanum majorana, Embelia ribes and Butea monosperma with Gas chromatography-mass spectrometry analysis of phytochemical property of plant extracts against Candida species causing dermatological

Abstract

Listen

Translate article

: Globally, fungi infections cause more than 1.5 million fatalities annually, mostly in those with weakened immune systems with Candida albicans found to be the chief pathogen. Approximately one to two billion people are affected by dermatological fungal infections involving skin and skin appendages, perhaps very difficult to estimate its exact prevalence due to under-reporting, this augments the requirements for more attention towards new molecules to combat resistance.: Evaluation of antifungal activity of Piper longum, Origanum majorana, Embelia ribes, Butea monosperma both in-vivo and in-vitro analysis against Candida species. This experimental study conducted for evaluating both in-vitro as well as in-vivo anti-fungal activity of Piper longum, Butea monosperma, Embelia ribes and Origanum majorana, and evaluation of phytoconstituent through Gas Chromatography and Mass Spectrometry analysis by GC-MS-QP-2010 plus system to identify the active bio-component. Fluconazole used as the standard control in-vivo and Itraconazole used as a standard drug for in-vitro infection and analysis. Ethical Committee approval was taken (IMS, BHU Dean/2018/CAEC/818). The antifungal activity of the extracts in-vitro was evaluated by Resazurin microtiter assay against Candida sp. Micro broth dilution methods. Rats were given an injection of 0.2 mL (intravenously/i.v) of a 10° UFC/mL inoculum made from a fresh 48-hour Candida albicans culture in sterile saline to cause infection. Induction of candidemia in rats was confirmed using qualitative Gram-stained smear. : The extracts of Butea monosperma (Alc.), Piper longum (Alc.), Origanum majorana (Aq.), and Piper longum (Aq.) showed effective antifungal activity against Candida sp. in-vitro research with a minimum inhibitory concentration (MIC) of less than 0.25 mg/mL. : This study is contributing towards the search for a natural drug candidate to combat resistance caused by the Candida genus, as it is one of the highest contributors to fungal dermatological/skin infections.